Sedative-Hypnotic Drugs

Correct Answer

A — Diazepam

Rationale

Diazepam is classified as the preferred long-acting agent for benzodiazepine taper conversion. A patient dependent on a short-acting, high-potency benzodiazepine such as alprazolam is first converted to an equivalent diazepam dose before beginning the structured reduction. Cross-dependence ensures diazepam fully suppresses withdrawal, while its prolonged half-life eliminates inter-dose withdrawal symptoms and provides self-tapering kinetics as the dose is gradually reduced. Lorazepam is intermediate-acting and reserved for patients with hepatic disease. Alprazolam and triazolam are short-acting agents — the agents being tapered away from, not converted to.

Correct Answer

C — Sodium channel blocker

Rationale

Carbamazepine is classified as a sodium channel blocker. Its mechanism includes voltage-gated sodium channel blockade and modulation of kindling phenomena, which is the pharmacological basis for its use as an adjunctive agent to reduce withdrawal symptom severity and seizure risk during benzodiazepine tapering. Alpha-2-delta calcium channel modulation describes pregabalin and gabapentin — also used as adjuncts during taper but with a different mechanism and less robust evidence. Gamma-aminobutyric acid type A positive allosteric modulation describes benzodiazepines and barbiturates. Serotonin-norepinephrine reuptake inhibition describes antidepressants sometimes started during taper to treat the underlying anxiety disorder.

Correct Answer

B — Lorazepam and oxazepam

Rationale

Lorazepam and oxazepam — members of the glucuronidation group alongside temazepam — are the preferred agents for alcohol withdrawal management in patients with significant hepatic disease. These agents undergo glucuronidation rather than cytochrome P450-mediated oxidative metabolism, a pathway that is relatively preserved in hepatic impairment. They also produce no pharmacologically active metabolites, preventing drug accumulation in patients with reduced hepatic clearance. Diazepam and chlordiazepoxide are preferred in medically stable patients without hepatic disease due to their self-tapering kinetics, but their active metabolites accumulate dangerously in liver failure. Clonazepam, alprazolam, midazolam, and triazolam are not classified as the preferred agents for this specific clinical indication.

Correct Answer

D — Vitamin B1

Rationale

Thiamine is vitamin B1, a water-soluble B-complex vitamin that serves as an essential cofactor for several enzymatic reactions in carbohydrate metabolism, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Vitamin B6 is pyridoxine, involved in amino acid metabolism. Vitamin B12 is cobalamin, required for nucleotide synthesis and myelin maintenance. Vitamin B9 is folate, required for nucleotide biosynthesis and neural tube development. Knowing that thiamine is vitamin B1 is foundational classification knowledge in the pharmacological management of alcohol use disorder.

Correct Answer

A — Isolated benzodiazepine exposure only, with no physical dependence, no tricyclic antidepressant co-ingestion, and no seizure history

Rationale

Flumazenil is classified as appropriate only in a narrow set of circumstances in overdose: isolated benzodiazepine exposure without physical dependence, no tricyclic antidepressant co-ingestion, and no seizure history. In clinical practice it is contraindicated far more often than it is indicated, given the high prevalence of co-ingestants and dependence in emergency presentations. It is not appropriate for patients with dependence, because reversal of benzodiazepine effect precipitates acute withdrawal including seizures. It must not be given when tricyclic antidepressant co-ingestion is possible, because removing benzodiazepine-mediated seizure suppression can unmask refractory seizures. It has no effect on barbiturates, Z-drugs, propofol, or other sedative-hypnotics.

Correct Answer

C — Phenobarbital

Rationale

Phenobarbital is the sedative-hypnotic agent for which enhanced elimination techniques are clinically applicable in overdose. Multiple-dose activated charcoal administered every four to six hours interrupts the enterohepatic recirculation of phenobarbital, increasing its overall elimination rate. Urinary alkalinization with sodium bicarbonate — targeting a urine pH of 7.5 to 8.0 — promotes ion trapping of phenobarbital in the renal tubule, increasing its urinary excretion. Hemodialysis is reserved for life-threatening phenobarbital toxicity unresponsive to supportive care. These enhanced elimination strategies are not applicable to benzodiazepines such as diazepam or lorazepam, nor to Z-drugs such as zolpidem, which do not undergo enterohepatic recirculation and are not ion-trapped at achievable urine pH values.

Correct Answer

D — All gamma-aminobutyric acid type A-active drugs share cross-dependence; the receptor downregulation driving alcohol withdrawal is the same neuroadaptation that benzodiazepines can reverse

Rationale

Chronic alcohol use produces compensatory downregulation of gamma-aminobutyric acid type A receptors — the same receptor system modulated by benzodiazepines. Because all gamma-aminobutyric acid type A-active agents induce identical neuroadaptive changes at the receptor level, any member of this class can suppress withdrawal from any other. This shared pharmacological basis is called cross-dependence, and it is why benzodiazepines treat alcohol withdrawal, why phenobarbital treats both alcohol and benzodiazepine withdrawal, and why a patient dependent on alcohol will require higher-than-usual doses of a benzodiazepine to achieve a given clinical effect. Benzodiazepines do not metabolize alcohol, do not act at mu-opioid receptors, and do not directly block N-methyl-D-aspartate receptors.

Correct Answer

B — Supplemental oxygen maintains oxygen saturation despite hypoventilation and carbon dioxide retention; capnography detects rising end-tidal carbon dioxide earlier

Rationale

Pulse oximetry measures oxygen saturation of hemoglobin, not ventilatory adequacy. In a patient receiving supplemental oxygen, the increased inspired oxygen concentration maintains adequate hemoglobin saturation even as respiratory rate and tidal volume fall and carbon dioxide accumulates from hypoventilation. This creates a window during which the patient is hypoventilating — and worsening — while the pulse oximetry reading appears normal. Capnography measures end-tidal carbon dioxide, which rises with hypoventilation regardless of supplemental oxygen. This makes capnography the preferred monitoring modality for detecting respiratory depression in sedative-hypnotic overdose. Benzodiazepines do not alter hemoglobin oxygen affinity, and diazepam does not inhibit chemoreceptors or interfere with pulse oximetry signal generation.

Correct Answer

A — Phenobarbital directly activates gamma-aminobutyric acid type A channels without requiring gamma-aminobutyric acid, bypassing receptor downregulation that limits benzodiazepine efficacy; inhibits alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors; and its long half-life provides self-tapering coverage

Rationale

The pharmacological rationale for phenobarbital in severe alcohol withdrawal is threefold. First, at loading concentrations, phenobarbital directly activates gamma-aminobutyric acid type A chloride channels without requiring gamma-aminobutyric acid — bypassing the receptor downregulation that progressively limits benzodiazepine efficacy as withdrawal severity increases. Second, phenobarbital inhibits alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors, attenuating the excitatory pathophysiology that drives seizures and delirium. Third, its half-life of 80 to 120 hours provides sustained, self-tapering coverage without requiring frequent redosing. Phenobarbital does not block N-methyl-D-aspartate receptors as its primary mechanism in this context, has a longer rather than shorter half-life than diazepam, and has no specific reversal agent.

Correct Answer

C — Activated charcoal binds phenobarbital secreted into the gut lumen via enterohepatic recirculation, preventing its reabsorption and increasing net elimination

Rationale

Phenobarbital undergoes enterohepatic recirculation: after hepatic metabolism, a portion is secreted into the bile and enters the intestinal lumen, where it can be reabsorbed and returned to systemic circulation. Multiple-dose activated charcoal placed in the gut interrupts this cycle by binding phenobarbital each time it is secreted into the intestinal lumen, preventing reabsorption and creating a sustained pharmacokinetic sink that accelerates net drug elimination. This mechanism is distinct from the initial dose of activated charcoal given within one to two hours of ingestion to prevent primary absorption. Activated charcoal does not enter the bloodstream to bind drug directly, does not alkalinize the gut, and does not affect intestinal motility in a clinically meaningful way.

Correct Answer

D — Alkaline urine causes phenobarbital, a weak acid, to ionize in the tubule lumen, trapping it in a charged form that cannot be reabsorbed across the tubular membrane

Rationale

Phenobarbital is a weak acid. In its uncharged form it can diffuse passively across the lipid bilayer of renal tubular cells, allowing reabsorption into the bloodstream. When the urine is alkalinized to pH 7.5 to 8.0, phenobarbital is converted to its ionized (charged) form by losing a proton to the alkaline environment. The ionized form cannot cross the tubular membrane, trapping phenobarbital within the tubule lumen where it is carried out in the urine rather than being reabsorbed. This ion-trapping principle applies to all weak acids and is the pharmacokinetic basis for urinary alkalinization in phenobarbital overdose. Alkalinization does not alter glomerular filtration rate, inhibit hepatic enzymes, or change plasma protein binding in a clinically useful way for this purpose.

Correct Answer

B — Each fixed-percentage reduction at a lower total dose represents a larger proportional change in receptor occupancy, making withdrawal symptoms more likely

Rationale

The pharmacodynamic basis for slowing the taper rate at lower doses lies in the relationship between dose, receptor occupancy, and proportional change. A reduction of 10 percent from a high dose — for example, reducing from 40 milligrams to 36 milligrams of diazepam — produces a relatively small proportional change in gamma-aminobutyric acid type A receptor occupancy compared to a 10 percent reduction from a low dose, such as from 4 milligrams to 3.6 milligrams. At the lower end of the taper, each milligram reduction has a larger pharmacodynamic impact, making the nervous system more vulnerable to inter-dose withdrawal. Evidence supports reducing at 5 percent or less per two weeks during the final stages of a taper. The blood-brain barrier permeability does not change in this context, and the mechanism is receptor occupancy pharmacodynamics rather than altered metabolism or receptor upregulation.

Correct Answer

A — Glucose administration increases metabolic demand for thiamine as a cofactor; in a thiamine-depleted patient this can precipitate Wernicke encephalopathy

Rationale

Thiamine is an essential cofactor for three key enzymes in carbohydrate metabolism: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase. When glucose is administered to a thiamine-depleted patient, the increased metabolic substrate drives these enzymatic reactions harder, rapidly exhausting the already-depleted thiamine stores. Neurons in vulnerable regions — particularly the mammillary bodies and periaqueductal gray — cannot maintain aerobic metabolism and undergo injury, producing Wernicke encephalopathy characterized by the clinical triad of ophthalmoplegia, ataxia, and confusion. Glucose and thiamine do not share intestinal transporters, intravenous glucose does not dilute thiamine to clinically meaningful levels, and thiamine does not activate glucose transporters.

Correct Answer

C — Autonomic hyperactivity from 6 to 24 hours, peak seizure risk from 24 to 48 hours, and delirium tremens from 48 to 96 hours

Rationale

Alcohol withdrawal follows a predictable three-phase temporal progression. The early withdrawal phase, 6 to 24 hours after last drink, is characterized by tremor, anxiety, tachycardia, hypertension, diaphoresis, and nausea — manifestations of autonomic hyperactivity from loss of gamma-aminobutyric acid inhibitory tone. The seizure risk window peaks from 24 to 48 hours, with most alcohol withdrawal seizures occurring as single generalized tonic-clonic events during this period; status epilepticus occurs in approximately 3 percent. Delirium tremens — the most dangerous phase, with confusion, agitation, visual hallucinations, autonomic instability, and hyperthermia — develops between 48 and 96 hours after cessation and carries a mortality of 5 to 15 percent even with treatment.

Correct Answer

B — At loading concentrations, phenobarbital directly activates gamma-aminobutyric acid type A channels without requiring gamma-aminobutyric acid, bypassing the receptor downregulation that limits lorazepam efficacy in severe withdrawal

Rationale

In severe alcohol withdrawal, sustained excitatory activity drives gamma-aminobutyric acid type A receptor internalization and downregulation — progressively reducing the surface receptor pool available for benzodiazepine enhancement. Lorazepam, like all benzodiazepines, requires gamma-aminobutyric acid to be present and a functional receptor to bind — it cannot work when the receptor population is severely depleted. Phenobarbital at loading concentrations directly activates gamma-aminobutyric acid type A chloride channels without requiring gamma-aminobutyric acid, bypassing the downregulated receptor system entirely. This mechanistic difference, not pharmacokinetics, is the reason phenobarbital retains efficacy when benzodiazepines have failed. Phenobarbital does not act at mu-opioid receptors and does not bind the benzodiazepine site to displace lorazepam.

Correct Answer

D — Supplemental oxygen maintains oxygen saturation even as carbon dioxide rises from hypoventilation; capnography measures end-tidal carbon dioxide and detects the hypoventilation before oxygen saturation falls

Rationale

Pulse oximetry measures the oxygen saturation of hemoglobin, not ventilatory adequacy. When a hypoventilating patient is receiving supplemental oxygen, the elevated inspired oxygen fraction maintains hemoglobin saturation at near-normal levels even as alveolar ventilation falls and carbon dioxide accumulates. This creates a window of apparent reassurance during which the patient is worsening. Capnography measures end-tidal carbon dioxide in exhaled breath — a direct indicator of ventilatory adequacy that rises with hypoventilation regardless of inspired oxygen concentration. Capnography therefore detects respiratory depression substantially earlier than pulse oximetry in patients on supplemental oxygen. Alprazolam does not alter hemoglobin oxygen affinity, pulse oximetry is a continuous measurement not limited by respiratory rate, and an electroencephalogram is not a monitoring tool for respiratory depression.

Correct Answer

A — Cross-dependence ensures diazepam fully suppresses alprazolam withdrawal, while diazepam's long half-life eliminates inter-dose withdrawal symptoms and provides self-tapering pharmacokinetics during the reduction

Rationale

The conversion from alprazolam to diazepam before tapering exploits two pharmacological principles. First, cross-dependence: because both drugs act at the same gamma-aminobutyric acid type A receptor system, diazepam fully substitutes for alprazolam and suppresses the withdrawal that would occur if alprazolam were simply reduced. Second, pharmacokinetics: diazepam's half-life of 20 to 100 hours, extended further by its active metabolite desmethyldiazepam, provides stable, sustained receptor occupancy that eliminates the inter-dose withdrawal spikes that occur with short-acting, high-potency alprazolam. As the diazepam dose is gradually reduced, the long half-life also provides a degree of self-tapering. The conversion is not based on receptor affinity differences, active metabolite displacement, or a different anxiolytic-to-sedative ratio.

Correct Answer

C — Glucose administration increased metabolic demand for thiamine as a cofactor; in a thiamine-depleted patient, this exhausted remaining thiamine stores and precipitated Wernicke encephalopathy

Rationale

Thiamine is an essential cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase — three enzymes central to carbohydrate metabolism and the citric acid cycle. In a patient with alcohol use disorder, chronic poor nutrition and alcohol's interference with thiamine absorption produce thiamine depletion. When glucose is administered, the increased metabolic substrate drives these thiamine-dependent reactions harder, rapidly exhausting the already-depleted thiamine stores. Neurons in vulnerable regions — particularly the mammillary bodies and periaqueductal gray — cannot sustain aerobic metabolism and undergo injury, producing the clinical triad of Wernicke encephalopathy: ophthalmoplegia, ataxia, and confusion. Thiamine must be administered before or alongside any glucose-containing solution in patients with known or suspected alcohol use disorder. Dextrose does not cause osmotic blood-brain barrier disruption at clinical doses, does not inhibit intestinal thiamine transporters, and does not suppress gamma-aminobutyric acid type A receptors through hyperglycemia.